Synthesis of novel pyrazoline derivatives and evaluation of their antimicrobial activity

Year 2022, Volume: 26 Issue: 5, 1453 - 1460, 28.06.2025

Fatih Tok , Muhammed Oğuzhan Doğan Burçak Gürbüz , Bedia Kaymakçıoğlu

https://izlik.org/JA23TR78UH

Abstract

In this study, new nine pyrazoline derivatives were synthesized from chalcone derivatives. The
antimicrobial activity of nine pyrazoline derivatives to four standard bacterial strains (Staphylococcus aureus, Escherichia
coli, Pseudomonas aeruginosa, Enterococcus faecalis) and four standard yeast strains (Candida albicans, Candida glabrata,
Candida parapsilosis, Candida tropicalis) was investigated by the microdilution method for in accordance with the Clinical
and Laboratory Standards Institute (CLSI) standard, and the Minimal Inhibitory Concentration (MIC) values of these
derivatives were determined. Among these derivatives; compounds 7 and 8 against bacterial strains and compounds 2
and 3 against yeast strains exhibited good antimicrobial activity.

Keywords

Pyrazoline , bacteria , yeast , MIC

References

• [1] Mitcheltree MJ, Pisipati A, Syroegin EA, Silvestre KJ, Klepacki D, Mason JD, Terwilliger DW, Testolin G, Pote AR, Wu KJY, Ladley RP, Chatman K, Mankin AS, Polikanov YS, Myers AG. A synthetic antibiotic class overcoming bacterial multidrug resistance. Nature. 2021; 599: 507-512. [CrossRef]
• [2] Yılancıoğlu K. Antimicrobial drug interactions: systematic evaluation of protein and nucleic acid synthesis inhibitors. Antibiotics. 2019; 8(3): 1-8. [CrossRef]
• [3] Sroor FM, Othman AM, Tantawy MA, Mahrous KF, El-Naggar ME. Synthesis, antimicrobial, anti-cancer and in silico studies of new urea derivatives. Bioorg Chem. 2021; 112: 1-15. [CrossRef]
• [4] Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015; 109(7): 309–318. [CrossRef]
• [5] Ahmad A, Husain A, Khan SA, Mujeeb M, Bhandari A. Synthesis, antimicrobial and antitubercular activities of some novel pyrazoline derivatives. J Saudi Chem Soc. 2016; 20(5): 577-584. [CrossRef]
• [6] Siddiqui ZN, Musthafa TNM, Ahmad A, Khan AU. Thermal solvent-free synthesis of novel pyrazolyl chalcones and pyrazolines as potential antimicrobial agents. Bioorg Med Chem Lett. 2011; 21(10): 2860-2865. [CrossRef]
• [7] Shaik AB, Yejella RP, Shaik S. Synthesis, Antimicrobial, and Computational Evaluation of Novel Isobutylchalcones as Antimicrobial Agents. Int J Med Chem. 2017; 2017: 1-14. [CrossRef]
• [8] Tok F, Koçyiğit-Kaymakçıoğlu B, Sağlık BN, Levent S, Özkay Y, Kaplancıklı ZA. Synthesis and biological evaluation of new pyrazolone Schiff bases as monoamine oxidase and cholinesterase inhibitors. Bioorg Chem. 2019; 84: 41-50. [CrossRef]
• [9] Kaplancıklı ZA, Özdemir A, Turan-Zitouni G, Altıntop MD, Can ÖD. New pyrazoline derivatives and their antidepressant activity. Eur J Med Chem. 2010; 45(9): 4383-4387. [CrossRef]
• [10] Kaplancıklı ZA, Turan-Zitouni G, Özdemir A, Can ÖD, Chevallet P. Synthesis and antinociceptive activities of some pyrazoline derivatives. Eur J Med Chem. 2009; 44(6): 2606-2610. [CrossRef]
• [11] Naim MJ, Alam O, Nawaz F, Alam MJ, Alam P. Current status of pyrazole and its biological activities. J Pharm Bioall Sci. 2016; 8(1): 2-17. [CrossRef]
• [12] Sağlık BN, Kaya Çavuşoğlu B, Acar Çevik U, Osmaniye D, Levent S, Özkay Y, Kaplancıklı ZA. Novel 1,3,4-thiadiazole compounds as potential MAO-A inhibitors – design, synthesis, biological evaluation and molecular modelling. RSC Med Chem. 2020; 11: 1063-1074. [CrossRef]
• [13] Tok F, Koçyiğit-Kaymakçıoğlu B. Design, synthesis and biological screening of novel 1,5-diphenyl-3-(4- (trifluoromethyl)phenyl)-2-pyrazoline derivatives. Acta Chim Slov. 2020; 67: 1139–1147. [CrossRef]
• [14] Tok F, Baltaş N, Tatar G, Koçyiğit-Kaymakçıoğlu B. Synthesis, biological evaluation and in silico studies of new pyrazoline derivatives bearing benzo[d]thiazol-2(3h)-one moiety as potential urease ınhibitors. Chem Biodiversity. 2022; 19: 1-11. [CrossRef]
• [15] Clinical and Laboratory Standards Institute (CLSI), Performance Standarts for Antimicrobial Susceptibility Testing. 30th Ed, January CLSI supplement M100 Wayne, PA: Clinical and Laboratory Standarts Institue; 2020.
• [16] Clinical and Laboratory Standards Institute (CLSI), Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; 4th Informational Supplement, M27-S4. CLSI, Wayne PA, USA. 2012.
• [17] Berkow EL, Lockhart SR, Ostrosky-Zeichner L. Antifungal susceptibility testing: current approaches. Clin Microbiol Rev. 2020; 33(3). e00069-19. [CrossRef]